BPG is committed to discovery and dissemination of knowledge
Featured Articles
5/19/2023 10:34:41 AM | Browse: 31 | Download: 24
Publication Name |
World Journal of Clinical Oncology |
Manuscript ID |
83164 |
Country/Territory |
United States |
 |
Received |
|
2023-01-09 21:23 |
 |
Peer-Review Started |
|
2023-01-09 21:25 |
 |
To Make the First Decision |
|
|
 |
Return for Revision |
|
2023-01-31 08:53 |
 |
Revised |
|
2023-02-28 16:49 |
 |
Second Decision |
|
2023-04-21 03:02 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Company Editor-in-Chief |
|
2023-04-21 08:03 |
 |
Articles in Press |
|
2023-04-21 08:03 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2023-05-11 09:16 |
 |
Publish the Manuscript Online |
|
2023-05-19 06:25 |
ISSN |
2218-4333 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Oncology |
Manuscript Type |
Minireviews |
Article Title |
Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer
|
Manuscript Source |
Invited Manuscript |
All Author List |
Aya Abunada, Zaid Sirhan, Anita Thyagarajan and Ravi P Sahu |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Elsa U. Pardee Foundation grant |
671432 |
NIH R21 grant |
ES033806 |
|
Corresponding Author |
Ravi P Sahu, BSc, MSc, PhD, Assistant Professor, Department of Pharmacology and Toxicology, Boonshoft School of Medicine Wright State University, 230 Health Sciences Bldg, 3640 Colonel Glenn Hwy, Dayton, OH 45435, United States. ravi.sahu@wright.edu |
Key Words |
Human epidermal growth factor receptor-2 positive breast cancer; Tyrosine kinase inhibitors; Lapatinib; Pyrotinib; Tucatinib; Trastuzumab |
Core Tip |
Newly published randomized controlled trials within the past two years have provided compelling evidence on the use of tyrosine kinase inhibitors (TKIs) such as Lapatinib, Pyrotinib, Neratinib, Tucatinib, Ruxolitinib, and Afatinib. Several of these agents were found to offer better outcomes in terms of progression-free survival when combined with other agents. While some TKIs, namely Lapatinib, and Neratinib, are supported with a large amount of data than others, the medical literature still lacks substantial evidence to draw a clinical conclusion that could modify/add to the present recommendations in human epidermal growth factor receptor-2 positive breast cancer treatment guidelines. |
Publish Date |
2023-05-19 06:25 |
Citation |
Abunada A, Sirhan Z, Thyagarajan A, Sahu RP. Tyrosine kinase inhibitors and human epidermal growth factor receptor-2 positive breast cancer. World J Clin Oncol 2023; 14(5): 198-202 |
URL |
https://www.wjgnet.com/2218-4333/full/v14/i5/198.htm |
DOI |
https://dx.doi.org/10.5306/wjco.v14.i5.198 |
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345